vs
Side-by-side financial comparison of CareTrust REIT, Inc. (CTRE) and IDEAYA Biosciences, Inc. (IDYA). Click either name above to swap in a different company.
IDEAYA Biosciences, Inc. is the larger business by last-quarter revenue ($207.8M vs $134.9M, roughly 1.5× CareTrust REIT, Inc.). CareTrust REIT, Inc. runs the higher net margin — 82.5% vs 57.4%, a 25.1% gap on every dollar of revenue.
CareTrust REIT, Inc.CTREEarnings & Financial Report
Target Healthcare REIT is a British property investment company which invests in healthcare properties and holds a large portfolio of care homes. It is structured as a real estate investment trust (REIT) and is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.
IDEAYA Biosciences, Inc. is a clinical-stage biotechnology company focused on oncology, developing targeted therapies and synthetic lethality treatments for patients with genetically defined cancers. It advances a pipeline of candidates across multiple tumor types, partnering with industry stakeholders to accelerate global access to innovative cancer care solutions.
CTRE vs IDYA — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $134.9M | $207.8M |
| Net Profit | $111.3M | $119.2M |
| Gross Margin | — | — |
| Operating Margin | — | 52.2% |
| Net Margin | 82.5% | 57.4% |
| Revenue YoY | 55.1% | — |
| Net Profit YoY | 113.5% | 330.1% |
| EPS (diluted) | $0.52 | $1.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $134.9M | — | ||
| Q3 25 | $132.4M | $207.8M | ||
| Q2 25 | $112.5M | — | ||
| Q1 25 | $96.6M | — | ||
| Q4 24 | $86.9M | — | ||
| Q3 24 | $77.4M | $0 | ||
| Q2 24 | $68.9M | $0 | ||
| Q1 24 | $63.1M | $0 |
| Q4 25 | $111.3M | — | ||
| Q3 25 | $74.9M | $119.2M | ||
| Q2 25 | $68.5M | — | ||
| Q1 25 | $65.8M | — | ||
| Q4 24 | $52.1M | — | ||
| Q3 24 | $33.4M | $-51.8M | ||
| Q2 24 | $10.8M | $-52.8M | ||
| Q1 24 | $28.7M | $-39.6M |
| Q4 25 | — | — | ||
| Q3 25 | 58.1% | 52.2% | ||
| Q2 25 | 61.3% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 43.0% | — | ||
| Q2 24 | 15.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 82.5% | — | ||
| Q3 25 | 56.6% | 57.4% | ||
| Q2 25 | 60.9% | — | ||
| Q1 25 | 68.1% | — | ||
| Q4 24 | 60.0% | — | ||
| Q3 24 | 43.2% | — | ||
| Q2 24 | 15.6% | — | ||
| Q1 24 | 45.6% | — |
| Q4 25 | $0.52 | — | ||
| Q3 25 | $0.35 | $1.33 | ||
| Q2 25 | $0.35 | — | ||
| Q1 25 | $0.35 | — | ||
| Q4 24 | $0.30 | — | ||
| Q3 24 | $0.21 | $-0.60 | ||
| Q2 24 | $0.07 | $-0.68 | ||
| Q1 24 | $0.22 | $-0.53 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.0M | $786.9M |
| Total DebtLower is stronger | $894.2M | — |
| Stockholders' EquityBook value | $4.0B | $1.1B |
| Total Assets | $5.1B | $1.2B |
| Debt / EquityLower = less leverage | 0.22× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $198.0M | — | ||
| Q3 25 | $712.5M | $786.9M | ||
| Q2 25 | $306.1M | — | ||
| Q1 25 | $26.5M | — | ||
| Q4 24 | $213.8M | — | ||
| Q3 24 | $377.1M | $920.0M | ||
| Q2 24 | $495.1M | $701.7M | ||
| Q1 24 | $451.2M | $698.8M |
| Q4 25 | $894.2M | — | ||
| Q3 25 | $893.8M | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $822.1M | — | ||
| Q4 24 | $396.9M | — | ||
| Q3 24 | $396.7M | — | ||
| Q2 24 | $671.1M | — | ||
| Q1 24 | $595.9M | — |
| Q4 25 | $4.0B | — | ||
| Q3 25 | $4.0B | $1.1B | ||
| Q2 25 | $3.3B | — | ||
| Q1 25 | $2.9B | — | ||
| Q4 24 | $2.9B | — | ||
| Q3 24 | $2.4B | $1.2B | ||
| Q2 24 | $1.9B | $931.7M | ||
| Q1 24 | $1.7B | $935.3M |
| Q4 25 | $5.1B | — | ||
| Q3 25 | $5.1B | $1.2B | ||
| Q2 25 | $4.7B | — | ||
| Q1 25 | $3.9B | — | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $2.9B | $1.2B | ||
| Q2 24 | $2.7B | $973.7M | ||
| Q1 24 | $2.3B | $961.5M |
| Q4 25 | 0.22× | — | ||
| Q3 25 | 0.22× | — | ||
| Q2 25 | 0.35× | — | ||
| Q1 25 | 0.28× | — | ||
| Q4 24 | 0.14× | — | ||
| Q3 24 | 0.16× | — | ||
| Q2 24 | 0.35× | — | ||
| Q1 24 | 0.36× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $394.0M | $142.2M |
| Free Cash FlowOCF − Capex | — | $142.2M |
| FCF MarginFCF / Revenue | — | 68.4% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | 3.54× | 1.19× |
| TTM Free Cash FlowTrailing 4 quarters | — | $13.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $394.0M | — | ||
| Q3 25 | $100.9M | $142.2M | ||
| Q2 25 | $100.8M | — | ||
| Q1 25 | $71.4M | — | ||
| Q4 24 | $244.3M | — | ||
| Q3 24 | $67.2M | $-49.2M | ||
| Q2 24 | $53.0M | $-32.9M | ||
| Q1 24 | $48.8M | $-43.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | $142.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-49.7M | ||
| Q2 24 | — | $-33.9M | ||
| Q1 24 | — | $-45.1M |
| Q4 25 | — | — | ||
| Q3 25 | — | 68.4% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 3.54× | — | ||
| Q3 25 | 1.35× | 1.19× | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 4.68× | — | ||
| Q3 24 | 2.01× | — | ||
| Q2 24 | 4.92× | — | ||
| Q1 24 | 1.70× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
